June 8, 2017 07:32 AM EDT

Genentech axes its $1B-plus IDO drug deal with NewLink in the wake of underwhelming data

John Carroll

Editor & Founder

Six days after Genentech rolled out disappointing early-stage data on its IDO1 drug GDC-0919 (navoximod) in-licensed from NewLink Genetics, the big Roche subsidiary is kicking …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Genentech axes its $1B-plus IDO drug deal with NewLink in the wake of underwhelming data

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Bristol Myers sues the federal government over 340B, following other drugmakers

Outlook's shares crash as wet AMD drug flunks Phase 3 test

Genen­tech ax­es its $1B-plus IDO drug deal with NewLink in the wake of un­der­whelm­ing da­ta

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Out­look's shares crash as wet AMD drug flunks Phase 3 test

Genentech axes its $1B-plus IDO drug deal with NewLink in the wake of underwhelming data

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Bristol Myers sues the federal government over 340B, following other drugmakers

Outlook's shares crash as wet AMD drug flunks Phase 3 test